MK-677 research: what the published trials report
The short version: MK-677 reliably raises IGF-1 in trials. Lean mass gains are real but modest. Side effects are not subtle. It is not approved for any indication.
TL;DR
- MK-677 is an oral growth hormone secretagogue developed by Merck and never approved.
- Trials show consistent IGF-1 elevation and small lean-mass gains in older adults.
- Common trial side effects include water retention, mild blood-sugar elevation, and increased appetite.
What it is
MK-677, also called ibutamoren, is a small molecule taken by mouth (in plain English: most peptides have to be injected, but this one survives the stomach because it is not a peptide). It mimics ghrelin (in plain English: the body's "hunger and growth-hormone-release" hormone). It binds the same receptor as ghrelin and triggers the pituitary to release growth hormone.
How it works
Picture the pituitary gland as a vending machine for growth hormone. Ghrelin is one of the buttons. MK-677 is a finger that presses that button on a steady, daily schedule. The pituitary releases growth hormone, which raises IGF-1 in the liver. Because the molecule survives oral dosing, it produces a more sustained signal than injected peptides. That sustained signal is also why the side effect profile differs (Murphy et al., J Endocrinol, 1997).
Who asks about it
People come to MK-677 because it is the only oral compound in the growth-hormone-peptide conversation. The question they bring is usually whether oral convenience is worth the trade-off in side effects.
What the research says
A two-month trial in healthy older adults showed daily oral MK-677 raised IGF-1 by roughly 40 to 90 percent and increased lean mass by about 1 to 1.5 kg. Fat mass did not change meaningfully, and fasting blood sugar rose modestly (Nass et al., Ann Intern Med, 2008). Earlier dose-response work confirmed the pituitary signal in healthy young adults (Murphy, J Endocrinol, 1997). Sleep architecture data is mixed; some trials show small increases in deep sleep, others none.
What to know before considering it
Side effects in published trials are not subtle. About 4 in 10 participants reported water retention, increased appetite, or muscle aches. Fasting blood sugar can rise. People with insulin resistance, active malignancy, or fluid-overload conditions should not use it. Any peptide or secretagogue access requires a licensed prescriber and baseline labs.
The Halftime POV
MK-677 has more trial data than most growth hormone peptides because Merck advanced it through phase II development. The trade-off is honest: the IGF-1 signal is reliable, and so are the side effects. It is not a casual choice.
Related reading:
- How MK-677 stimulates growth hormone: the ghrelin pathway
- MK-677 side effects: water retention, insulin, appetite, and more
- MK-677 (Ibutamoren): an oral growth-hormone secretagogue
FAQ
Q: What does MK-677 research show? A: Published trials show MK-677 raises IGF-1 by about 40 to 90 percent for as long as it is taken. Older adults gained roughly 1 to 1.5 kg of lean mass over two months in one trial. Sleep architecture data is mixed.
Q: Are there MK-677 human trials? A: Yes. Merck developed MK-677 (ibutamoren) and ran several trials in healthy older adults and in pediatric growth hormone deficiency. The compound was never approved for any indication.
Q: Is MK-677 FDA-approved? A: No. MK-677 is investigational and was never granted FDA approval. As of September 14, 2026, MK-677 (ibutamoren) is in FDA's 503A Category 2, which lists substances FDA says raise significant safety risks.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
Frequently asked questions
What does MK-677 research show?
Published trials show MK-677 raises IGF-1 by about 40 to 90 percent for as long as it is taken. Older adults gained roughly 1 to 1.5 kg of lean mass over two months in one trial. Sleep architecture data is mixed.
Are there MK-677 human trials?
Yes. Merck developed MK-677 (ibutamoren) and ran several trials in healthy older adults and in pediatric growth hormone deficiency. The compound was never approved for any indication.
Is MK-677 FDA-approved?
No. MK-677 is investigational and was never granted FDA approval. As of September 14, 2026, MK-677 (ibutamoren) is in FDA's 503A Category 2, which lists substances FDA says raise significant safety risks.
Keep reading
A licensed physician reviews your labs and builds your protocol.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.